SABCS 2022 | SABCS 2022: clinical trial highlights

Mafalda Oliveira, MD, PhD, Vall d’Hebron Institute of Oncology, Barcelona, Spain, shares her results from the San Antonio Breast Cancer Symposium (SABCS) 2022. The Phase III CAPItello-291 (NCT04305496) trial demonstrated an improved progression-free survival (PFS) with the pan AKT/PTEN kinase inhibitor capivasertib with fulvestrant in locally advanced or metastatic HR-positive, HER2-negative breast cancer, particularly in patients with an alteration in the PI3K pathway. Additionally, the POSITIVE (NCT02308085) trial demonstrated premenopausal patients receiving endocrine adjuvant therapy can safely interrupt endocrine treatment for a pregnancy. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.